Welsh CRO Simbec-Orion has agreed to run two late-stage trials, deals the company says affirm the strategy behind its 2014 merger.
Fast-expanding CRO genae is buying into clinical trial technology, acquiring a company that focuses on electronic data capture.
Irish CRO Icon is plotting a new so-called innovation hub in its native Ireland, planning to hire 200 workers as it builds out a data-minded expansion.
Despite posting an uptick in revenue last quarter, CRO giant Parexel International is slightly lowering its outlook for fiscal 2015, betting that its backlog of deals will eventually make up for some soft sales.
Parexel is leasing a North Carolina building from GlaxoSmithKline, part of a deal between the two in which the CRO will absorb some researchers on the way out as the drugmaker mounts a major restructuring.
Australia's Novotech has made a permanent home in Hong Kong, ditching its old office in favor of a larger space as it works to capitalize on the growing demand for clinical services in the region.
San Francisco's goBalto raised $12 million to push its clinical trial software, designed to expedite study startup.
The European Medicines Agency is recommending its member states stop selling drugs tied to improprieties at a GVK Biosciences facility in India.
PPD has amped up the biologics capabilities at its Irish manufacturing operation, opening a new lab devoted to the development of large-molecule treatments.
Drug developers commonly deal with a host of CROs as they work their way from preclinical testing to first-in-human trials, a process designed to maximize the strengths of each contractor. But a piecemeal approach to early-stage development can lead to costly delays, according to Covance, which is pitching an all-encompassing offering it claims can seamlessly shuttle molecules from animal studies to Phase II.
Cel-Sci, seeking $50 million from former partner inVentiv Health, will soon get its day in court against the CRO.
U.K. CRO Ergomed, which often shares the risks and rewards of R&D with its clients, grew its revenue by 14% in 2014, and the company hopes to ride a late-year boom into 2015.
In-transition drug developer AMRI has won a 10-year contract with the National Institutes of Health to help develop and manufacture neurological drugs.
The R&D innovators at Evotec have signed a deal to lend their drug discovery muscle to U.K. biotech C4X Discovery, hoping to develop selective drugs that can combat addiction without druggy side effects.
Catalent has signed a collaboration deal with pharma giant Sanofi, lending out its proprietary approach to crafting antibody-guided treatments.
CRO Clinipace, which has pulled the trigger on 5 acquisitions in as many years, raised $50 million in debt and equity to bankroll the next phase of its expansion effort.
Novartis, in the midst of a long-running effort to make clinical trials more efficient, has recruited Qualcomm to help it gather and store patient data from medical devices.
Novella Clinical, owned by Quintiles, struck a deal with the Cardiovascular Research Foundation to join forces on trial services, expanding their existing relationship to create a seamless offering for medical device developers.
Evotec, a risk-sharing R&D collaborator, has extended its relationship with biotech startup Padlock Therapeutics, inking a new deal that will see the pair progress into preclinical development.
X-Chem, a subsidiary of PPD, has signed a deal with Johnson & Johnson to provide its library of molecules to aid in the discovery of new treatments for inflammatory disease.